Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah S Burns

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Experimental Neurology|June 15, 2017
Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiationJanet L Oblinger, Sarah S Burns, Jie Huang, et al.
Communications Biology|March 20, 2026
Ref-1 drives ulcerative colitis induced systemic defects in hematopoietic cellsRamesh Kumar, Rahul Kanumuri, Sarah S Burns, et al.
Cancer Research|November 16, 2012
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growthSarah S Burns, Elena M Akhmametyeva, Janet L Oblinger, et al.
Neuro-Oncology|March 9, 2016
Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomasJanet L Oblinger, Sarah S Burns, Elena M Akhmametyeva, et al.
Molecular Cancer Therapeutics|December 19, 2019
Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other SarcomasLong-Sheng Chang, Janet L Oblinger, Sarah S Burns, et al.
Molecular Cancer Therapeutics|August 5, 2017
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma CellsMarisa A Fuse, Stephani Klingeman Plati, Sarah S Burns, et al.
Neuro-Oncology|July 23, 2011
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomasMatthew L Bush, Janet Oblinger, Victoria Brendel, et al.
Laryngoscope Investigative Otolaryngology|October 20, 2021
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomasD Bradley Welling, Katharine A Collier, Sarah S Burns, et al.
The Journal of Clinical Investigation|April 18, 2023
Obesity-induced inflammation exacerbates clonal hematopoiesisSanthosh Kumar Pasupuleti, Baskar Ramdas, Sarah S Burns, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Experimental Neurology|June 15, 2017
Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiationJanet L Oblinger, Sarah S Burns, Jie Huang, et al.
Communications Biology|March 20, 2026
Ref-1 drives ulcerative colitis induced systemic defects in hematopoietic cellsRamesh Kumar, Rahul Kanumuri, Sarah S Burns, et al.
Cancer Research|November 16, 2012
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growthSarah S Burns, Elena M Akhmametyeva, Janet L Oblinger, et al.
Neuro-Oncology|March 9, 2016
Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomasJanet L Oblinger, Sarah S Burns, Elena M Akhmametyeva, et al.
Molecular Cancer Therapeutics|December 19, 2019
Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other SarcomasLong-Sheng Chang, Janet L Oblinger, Sarah S Burns, et al.
Molecular Cancer Therapeutics|August 5, 2017
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma CellsMarisa A Fuse, Stephani Klingeman Plati, Sarah S Burns, et al.
Neuro-Oncology|July 23, 2011
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomasMatthew L Bush, Janet Oblinger, Victoria Brendel, et al.
Laryngoscope Investigative Otolaryngology|October 20, 2021
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomasD Bradley Welling, Katharine A Collier, Sarah S Burns, et al.
The Journal of Clinical Investigation|April 18, 2023
Obesity-induced inflammation exacerbates clonal hematopoiesisSanthosh Kumar Pasupuleti, Baskar Ramdas, Sarah S Burns, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Pageof 3